Activation of the PI3K pathway could directly regulate the downstream CCND1/CDK4/6 axis, suggesting that pharmacological blockade of this axis is a promising therapeutic strategy in iCCA. This evidence concerns the gene CDK4 and infantile convulsions and choreoathetosis.